About this trial
Pityriasis versicolor is a common superficial fungal infection caused by Malassezia species, characterized by hypo- or hyper-pigmented scaly patches on the skin. Topical antifungal agents are the mainstay of treatment. Ketoconazole has been widely used; however, newer agents such as luliconazole may offer improved efficacy and shorter treatment duration. This randomized controlled study aims to compare the efficacy and safety of topical luliconazole versus topical ketoconazole in patients with pityriasis versicolor. Treatment response will be assessed clinically and mycologically to determine comparative outcomes.
Eligibility criteria
Qualifiers
All patients diagnosed with pityriasis versicolor.
Disqualifiers
Immunocompromised patients
Trial design
Treatments tested in this trial
- Luliconazole Cream 1%
- Topical ketoconazole 2% cream
Treatment groups
Locations
Sponsors and collaborators
PAEC General Hospital, Islamabad
Lead sponsor
PAEC general hospital
Collaborator